Dear 43 Things Users,

10 years after introducing 43 Things to the world, we have decided we have met our last goal: completing the incredible experience that has been 43 Things. Please join us in giving one last cheer to all the folks who have shared their goals with the world, as well as all the people who have worked at The Robot Co-op to build this incredible website. We won a Webby Award, published a book, and brought happiness to a lot of people.

Starting today, 43 Things users can export their goals and entries from the site. Starting August 15, we will make the site “read only”. 43 Things users will still be able to view the site and export their content, but we won’t be taking any new content from users. We hope to leave the site up for folks to see and download their content until the end of the year. Ending on New Year’s Eve takes us full circle.

It has been a long ride (one of our original goals was to "build a company that lasts at least 2 years” - we beat that one!) While we wish the site could live on, it has suffered from a number of challenges - changes in how people use the site, the advertising industry, and how search engines view the site. We wish the outcome was different – but we’ve always been realistic about when our goals are met and when they aren't.

As of today, you will be able to download your goals and entries. See more about that on the FAQ page. Thanks for 10 great years of goal-setting and achieving.

- The Robots.

Export My Content
149 people want to do this.

go to the oscars


People doing this

See everyone

Recent activity

Charly Breathe 4 months ago

kiwinz32 6 months ago

Osman DINC 7 months ago

regdog 8 months ago

Jenna Stone 11 months ago

murphywilliams13 15 months ago

ontheseashores 16 months ago

wataroo 17 months ago

meshmesh10 17 months ago

abbyjordan_13i want to go to the oscars

i think it’d be fun to go. I would probably go with one of my friends, or a couple, and HOPEFULLY get seats near the front. It would be a good experience, since not that many people my age get to go, and probably never will. 21 months ago

abbyjordan_13 21 months ago

Evergreen17 21 months ago

floatingvibes 23 months ago

Ziama 23 months ago

spez 23 months ago

LavonVelver53 23 months ago

ryeiam 2 years ago

marta estefanía 2 years ago


i like going to the oscars 2 years ago

tazalicious 2 years ago

UncreativeName 2 years ago

1sunshine21 2 years ago

cat67 2 years ago

user19978 2 years ago

ramonknudsen1126A Particular Thing You Haven't Heard About HIF Signaling Pathway HIV Protease and heat shock protein

HIV-2 is naturally resistant to nonnucleoside reverse transcriptase inhibitors, to a fusion inhibitor, and to some of the proteaseinhibitors. Maraviroc is the 1st medication of the new anti-CCR5 medication class and is effective only on CCR5-tropic HIV-1. No previousstudies about HIV-two HIF Signaling Pathway,heat shock protein,HIV Proteasesusceptibility to maraviroc have been reported but. We made a phenotypic maraviroc susceptibilitytest utilizing a peripheral blood mononuclear cell type. We analyzed the maraviroc susceptibility of 13 R5HIV-two, 2 X4R5 HIV-2, and 2 CXCR4-tropic HIV-2 medical isolates. We also analyzed, with the exact protocol, one X4HIV-one and four R5 HIV-1 clinical isolates. For the R5 HIV-2 clinical isolates, the 50% useful focus for maravirocwas .80 nM , identical to that observed for the R5 HIV-1 isolates. The median maximumpercentage of inhibition in the R5 HIV-two isolates was 93% , equivalent to that observed in the R5 HIV-one isolates.As expected, both equally X4 HIV-one and HIV-2 had been really resistant to maraviroc. Our study confirmed for the first time that maravirocis energetic in vitro versus R5 HIV-2. The new applications we created will allow identification of HIV-2-infected individuals eligiblefor CCR5 inhibitor use and management of virological failure when getting a maraviroc-based mostly routine.

HIV-two is a retrovirus discovered a couple of a long time right after HIV-one. HIV-2infections are restricted chiefly to West Africa, includingGuinea-Bissau, Gambia, Senegal, and Guinea. Some Europeancountries are also involved with HIV-two infection, which represents5% of HIV infection in a series of sufferers in Portugal and two% of the new HIV infections in France .The HIV-one and HIV-two genomes differ by about 50 to 60% atthe nucleotide level. This kind of dissimilarities may be correlated with differentialresponses to some antiretrovirals, as observed with thenatural resistance of HIV-two to nonnucleoside reverse transcriptaseinhibitors and to the fusion inhibitor enfuvirtide and the decreasedsusceptibility to some protease inhibitors . Thenew class of CCR5 inhibitors, including maraviroc , is the firstone to have a cellular target, and so, it is expected not to be impactedby HIV genetic diversity and may possibly provide a new therapeuticopportunity for HIV-two infection. Even so, prior studiesshowed that HIV-2 isolates can use a broad variety of coreceptors invitro, including CCR5 and CXCR4 as effectively as choice coreceptors,as follows: CCR1-5, GPR15 , CCR8, and CXCR6 . The in vivo function of these alternative coreceptorsis still beneath concern having said that, it suggeststhat HIV-2 scientific isolates could be equipped to access a lot more coreceptorsthan these of HIV-1, a mechanism that might effect the antiviralactivity of maraviroc towards HIV-two.The only examine reporting on the in vitro phenotypic susceptibilityof HIV-two to CCR5 inhibitors was carried out applying nonlicensedCCR5 inhibitors, precursors of maraviroc, with only twoCCR5-working with HIV-two isolates utilized . In vivo, two situation reportsdescribed an early virological reaction with a a number of-medication salvageregimen containing maraviroc in two HIV-2-contaminated patientswith a multiresistant virus .The aims of this analyze have been to establish the viral tropism andphenotypic susceptibility to maraviroc of HIV-2 clinical isolates. EC50 and MPI values of the strains assessed in the analyze are depictedin Desk one.

Phenotypic susceptibility screening showed themaraviroc EC50 to be .eighty nM in the 13 R5 HIV-2 clinical isolates analyzed . Thetwo dual HIV-2 isolates showed EC50s of 9.40nMand increased than1,000 nM, respectively. Variations noticed in the benefits of the 2dual HIV-2 viruses may possibly be relevant to the proportion of X4 viruspresent in the mixture, ensuing in broadly distinct dose-responsecurves. Both equally of the X4 HIV-two isolates tried confirmed EC50s ofgreater than 1,000 nM, as observed with the X4 HIV-one virus. R5HIV-1 isolates showed an EC50 price to maraviroc of 2.37 nM.The median MPI of R5 HIV-two isolates was 93% .The MPIs had been twelve and fifty five% for the two twin HIV-2 isolates and for the two X4 HIV-two isolates. Beneath the same ailments, the medianHIV-1 MPI of R5 HIV-1 was 76 .No particular env place, in or in close proximity to the gp105 CCR5 bindingsite, was found to be associated with the degree of EC50 or MPI.In this examine, primarily based on a PBMC phenotypic susceptibilitymodel, the EC50 and MPI values received for R5 HIV-2 strains aresimilar to people received for R5 HIV-1 strains tested under thesame ailments. Also, the EC50s received with HIV-two arealso in a vary related to individuals earlier described for HIV-1 .Maraviroc is a competitive viral entry inhibitor that does not blockthe intracellular viral replication cycle. Consequently, a smaller selection of activatedPBMCs may well be infected, in the presence of maraviroc, andshould be in a position to produce a nonnegligible range of viral particles.This mode of motion might reveal that in our review, the MPI variesbetween 70 and100%inHIV-2as well as in HIV-1.PBMCassay stepsalso have intrinsic variability, like the quantities of infectedcells for the duration of the infection stage, the amount of viral replicative capacityof the clinical isolate, and CCR5 density variations at the surfaces of PBMCs concerning distinct PBMC swimming pools.

Even so, these differentpoints have been taken into account in our assay by quadruplicate determinationof each position and by the use of aPBMCpool of a few to fourpatients in just about every experiment.Until now, in HIV-1, MPI values have been noted applying aPBMC design in maraviroc-resistant strains only . This studyshowed variations in MPI levels among the PBMC type andrecombinant product that may well be explained by the detectionmethod of infection and the duration of the cultivation action .Discrepant effects are reported in the literature about the use ofalternative coreceptors by HIV-2, which could be correlated to thecell line utilized in the in vitro assay .In addition, two scientific studies employing distinct solution with PBMCs,one with homozygous _32-ccr5 PBMCs and the other with specificantagonists, showed that alternative coreceptors did not significantlyimpact viral replication on PBMCs . These findings,additional to the very similar antiretroviral action of maravirocobserved in opposition to HIV-two and HIV-one and the similar MPI rangeobserved in our study, strongly recommend that alternative coreceptorsdo not look to engage in a key function in HIV-two infection.In the present examine, we established up a phenotypic PBMC-based testand assessed for the 1st time that maraviroc is active in vitroagainst R5 HIV-two clinical isolates. Last but not least, the new instruments we developedwill permit identification of HIV-2-contaminated patients eligiblefor CCR5 inhibitor use and administration of virological failurewhen receiving a maraviroc-dependent program. 2 years ago

ramonknudsen1126 2 years ago

Monica Chen 2 years ago

user10722 2 years ago

user9537 2 years ago

user4457 2 years ago

See more:   Entries

People doing this are also doing these things:


I want to:
43 Things Login